停用口服双膦酸盐治疗绝经后骨质疏松对骨转换标志物和骨密度的影响
研究纳入曾参加2年随机研究的绝经后骨质疏松女性,在髋部骨密度T值>-2.5且临床认为适合停药者中开展2年观察性研究,评估停用伊班膦酸、阿仑膦酸或利塞膦酸后骨转换标志物和骨密度的变化。停药后所有组骨转换标志物升高、髋部骨密度下降,但均未回到治疗前基线值。
要点
- 停用口服双膦酸盐2年后,所有组骨转换标志物升高但未回到治疗前基线值。
- 停药96周后全髋骨密度变化为-1.6%(95%CI -1.9至-1.2,P<0.001)。
- 停药96周后腰椎骨密度变化为-0.6%(95%CI -1.1至-0.2,P=0.17),三组间无差异。
核心结论
- 停用双膦酸盐2年后,所有治疗组骨转换标志物升高、髋部骨密度下降,但均未回到治疗前基线值。
研究设计与样本
- 研究纳入曾参加2年随机研究的绝经后骨质疏松女性,该随机研究比较三种口服双膦酸盐(伊班膦酸、阿仑膦酸或利塞膦酸)。
- 随机研究结束时,髋部骨密度T值>-2.5且临床认为适合停药者受邀参加进一步2年观察性研究。
- 骨转换标志物用于评估生化反应,骨密度采用双能X线吸收法测量。
主要发现
- 停药后所有骨转换标志物升高,但截至48周仍低于治疗前基线,利塞膦酸组骨转换标志物抑制程度轻于阿仑膦酸和伊班膦酸组。
- 停药96周后双膦酸盐各组间无差异。
- 停药96周内全髋骨密度变化为-1.6%(95%CI -1.9至-1.2,P<0.001)。
- 停药96周内腰椎骨密度变化为-0.6%(95%CI -1.1至-0.2,P=0.17)。
- 三种双膦酸盐组间骨密度变化无差异(全髋P=0.85,腰椎P=0.48)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The antiresorptive potency varies between different bisphosphonates. We investigated the effect of stopping oral bisphosphonate treatment for postmenopausal osteoporosis (ibandronate, alendronate, risedronate) on BTMs and BMD. After stopping treatment, all three groups showed an increase in BTMs and a decrease in hip BMD; however, none returned to pre-treatment baseline values. INTRODUCTION: Bisphosphonates (BPs) continue to suppress bone turnover markers (BTMs) after treatment has stopped, leading to the suggestion that a pause in treatment could be considered for low-risk patients. Indirect comparisons suggest that after cessation of treatment, the effects on bone may differ between drugs. We investigated the effects of stopping oral BP treatments for postmenopausal osteoporosis on BTMs and bone mineral density (BMD). METHODS: We studied postmenopausal osteoporotic women who had previously taken part in a 2-year randomised study of three oral BPs (ibandronate, alendronate, or risedronate). At the end of the study, women with hip BMD T-score > - 2.5 and considered clinically appropriate to discontinue treatment were invited to participate in a further 2-year observational study. Biochemical response was assessed using BTMs, and BMD was measured by dual-energy X-ray absorptiometry. RESULTS: All BTMs increased after treatment withdrawal but remained below the pre-treatment baseline with less suppression of BTMs for the risedronate group compared to alendronate and ibandronate up to 48 weeks. There was no difference between the BP groups 96 weeks after stopping treatment. The change in BMD during the 96 weeks after stopping treatment was - 1.6% (95% CI - 1.9 to - 1.2, P < 0.001) for the total hip and - 0.6% (95% CI - 1.1 to - 0.2, P = 0.17) at the lumbar spine with no difference between the three BP groups (P = 0.85 and P = 0.48, respectively). CONCLUSION: For all treatment groups, there was an increase in BTMs and a decrease in hip BMD after stopping BPs for 2 years; however, none returned to pre-treatment baseline values.
引用
- Naylor KE, Bradburn M, Paggiosi MA, et al. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density. Osteoporos Int. 2018. PMID: 29525970. doi:10.1007/s00198-018-4460-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。